Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa issued stock options and RSUs as inducement awards for six new hires under its 2026 Inducement Plan, following Nasdaq Rule 5635(c)(4).

Rhea-AI Summary

Monte Rosa Therapeutics (GLUE) granted inducement equity awards to six newly hired non-executive employees under its 2026 Inducement Plan. The grants include non-qualified stock options to purchase an aggregate of 31,145 shares of common stock at an exercise price of $14.31 per share, equal to the Nasdaq closing price on September 1, 2026, the Grant Date. These options vest 25% on the first anniversary of the Grant Date and monthly in 36 equal installments thereafter, subject to continued service. The employees also received an aggregate of 6,440 restricted stock units, vesting 25% annually over four years from the Grant Date, subject to continued service. The awards were granted outside stockholder-approved equity plans, approved by the board’s independent compensation committee, and are intended as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Market Context

GLUE's September 1 investor-conference announcement was followed by a 2.65% price reaction before th...

Analysis

GLUE's September 1 investor-conference announcement was followed by a 2.65% price reaction before this release. The active ATM program and recent insider net selling add context and remain risks to monitor alongside employee awards.

Key Figures

New employees: 6 employees Option awards: 31,145 shares Option exercise price: $14.31 per share +5 more

8 metrics

New employees 6 employees Inducement awards

Option awards 31,145 shares Non-qualified stock options

Option exercise price $14.31 per share Closing price on September 1 Grant Date

Common stock par value $0.0001 per share Monte Rosa common stock

Initial option vesting 25% First anniversary of the Grant Date

Subsequent option vesting 36 equal monthly installments After the first anniversary

Restricted stock units 6,440 shares Aggregate inducement award

RSU vesting 25% over 4 anniversaries Subject to continued service

Historical Context

5 past events · Latest: Sep 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Investor conferences	Neutral	+2.6%	Management announced participation in two September healthcare investor conferences.
Aug 24	Phase 2 dosing	Positive	-3.7%	First patient was dosed in the MODeFIRe-1 Phase 2 prostate cancer study.
Aug 06	Quarterly earnings	Negative	+0.6%	Second-quarter results showed lower collaboration revenue and a wider net loss.
Jul 02	Inducement grants	Negative	-4.0%	The company granted options and restricted stock units to three new employees.
Jun 02	Inducement grants	Negative	-0.8%	The company granted options and restricted stock units to four new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior inducement-grant announcements were followed by negative reactions, while broader company-news reactions were mixed.

Key Terms

molecular glue degrader, non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4)

4 terms

molecular glue degrader technical

"developing novel molecular glue degrader (MGD)-based medicines"

A molecular glue degrader is a small drug-like molecule that acts like a tiny adhesive, sticking a specific disease-related protein to the cell’s natural disposal machinery so the protein is destroyed rather than merely blocked. Investors watch these compounds because they can turn previously untreatable targets into removable liabilities, potentially creating breakthrough therapies, shifting development risk, and offering strong commercial upside if clinical results and regulatory approval follow.

non-qualified stock options financial

"non-qualified stock options to purchase 31,145 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units for an aggregate of 6,440 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to six newly hired non-executive employees as a material inducement to commencing their employment with the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 31,145 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $14.31 as reported by Nasdaq on September 1, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 6,440 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of stockholder-approved equity incentive plans and are pursuant to the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

FAQ

What inducement equity awards did Monte Rosa Therapeutics (GLUE) grant on September 1, 2026?

Monte Rosa Therapeutics granted inducement equity awards to six newly hired non-executive employees, consisting of non-qualified stock options to purchase 31,145 shares of common stock and 6,440 restricted stock units, as a material inducement to their employment.

What is the exercise price and vesting schedule of the new Monte Rosa (GLUE) stock options?

The non-qualified stock options have an exercise price of $14.31 per share, equal to the Nasdaq closing price on September 1, 2026. They vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to continued service.

How do the restricted stock units from the Monte Rosa (GLUE) inducement grants vest?

The inducement restricted stock units cover an aggregate of 6,440 shares of Monte Rosa common stock. They vest in four equal annual installments of 25% each on the first four anniversaries of the September 1, 2026 Grant Date, subject to each employee’s continued service.

Under which plan were the new Monte Rosa (GLUE) inducement awards issued?

The inducement stock options and restricted stock units were issued under the Monte Rosa Therapeutics 2026 Inducement Plan. All awards were granted outside of stockholder-approved equity incentive plans as material inducements to employment, consistent with Nasdaq Listing Rule 5635(c)(4).

Who approved the Monte Rosa Therapeutics (GLUE) inducement equity awards and under what Nasdaq rule?

The awards were approved by the company’s compensation committee, composed solely of independent directors. They were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4), which permits such grants outside stockholder-approved plans.